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Abstract: 
Manganese (Mn) accumulation in the brain has been shown to alter the neurochemistry of the 
basal ganglia. Mn-induced alterations in dopamine biology are fairly well understood, but 
recently more evidence has emerged characterizing the role of γ-aminobutyric acid (GABA) in 
this dysfunction. The purpose of this study was to determine if the previously observed Mn-
induced increase in extracellular GABA (GABAEC) was due to altered GABA transporter (GAT) 
function, and whether Mn perturbs other amino acid neurotransmitters, namely taurine and 
glycine (known modulators of GABA). Extracellular GABA, taurine, and glycine concentrations 
were collected from the striatum of control (CN) or Mn-exposed Sprague–Dawley rats using in 
vivo microdialysis, and the GAT inhibitor nipecotic acid (NA) was used to probe GAT function. 
Tissue and extracellular Mn levels were significantly increased, and the Fe:Mn ratio was 
decreased 36-fold in the extracellular space due to Mn-exposure. NA led to a 2-fold increase in 
GABAEC of CNs, a response that was attenuated by Mn. Taurine responded inversely to GABA, 
and a novel 10-fold increase in taurine was observed after the removal of NA in CNs. Mn 
blunted this response and nearly abolished extracellular taurine throughout collection. Striatal 
taurine transporter (Slc6a6) mRNA levels were significantly increased with Mn-exposure, and 
Mn significantly increased 3H-Taurine uptake after 3-min exposure in primary rat astrocytes. 
These data suggest that Mn increases GABAEC by inhibiting the function of GAT, and that 
perturbed taurine homeostasis potentially impacts neural function by jeopardizing the 
osmoregulatory and neuromodulatory functions of taurine in the brain. 
 
Article: 
INTRODUCTION 
An essential trace element and a cofactor for several enzymes (Hurley and Keen, 1987), 
manganese (Mn) is involved in immune function, regulation of metabolism, reproduction, 
digestion, bone growth, and blood clotting (see review by Aschner et al., 2005). While frank 
manganese deficiency has not been clinically observed in humans, Mn toxicity, in particular Mn 
neurotoxicity, is of concern (Aschner et al., 2005 and Dobson et al., 2004). A recent study 
suggests that high levels on Mn in drinking water (>300 μg/L) are associated with reduced 
intellectual function in children (Wasserman et al., 2006) likely due to altered neurochemistry 
(Garcia et al., 2006, Anderson et al., 2008 and Anderson et al., 2009). Manganese neurotoxicity 
shares similarities with the neurodegenerative disorder Parkinson's disease (Beuter et al., 1994, 
Calne et al., 1994 and Pal et al., 1999), though the two are clinically distinct (Calne et al., 1994, 
Pal et al., 1999 and Perl and Olanow, 2007). Due to the similarities of Mn neurotoxicity with 
Parkinson's disease, most research in the area of Mn neurotoxicity has focused on its effect on 
the biology of dopamine. Recently it has become clear that alterations in the biology of other 
neurotransmitters are involved in the etiology of Mn neurotoxicity, with the most evidence 
concerning γ-aminobutyric acid (GABA) (Anderson et al., 2007a, Anderson et al., 2007b, 
Anderson et al., 2008, Garcia et al., 2006, Garcia et al., 2007 and Gwiazda et al., 2002). 
 
With the intriguing findings that striatal extracellular GABA (GABAEC) concentrations are 
higher due to Mn-exposure (Anderson et al., 2008), and uptake of 3H-GABA is attenuated by 
Mn-exposure in striatal synaptosomes ( [Anderson et al., 2007a] and [Anderson et al., 2007b]) 
despite no significant effect of Mn on GABA transporter (GAT) protein and mRNA levels 
(Anderson et al., 2008); we hypothesize that the functioning of the transporter is altered by Mn-
exposure leading to attenuation of GABA reuptake. Thus, we designed our current experiment to 
pharmacologically probe the functioning of GAT by administering a known uptake inhibitor, 
nipecotic acid (NA). NA has a high binding affinity for human GAT-1 and rat GAT-1 and -2, 
decreasing astrocyte and neuronal GABA uptake ( [Krogsgaard-Larsen, 1980] and [Krogsgaard-
Larsen et al., 2000]). We can, therefore, test GAT function by measuring the increase in 
GABAEC concentrations in the striatum of Mn-exposed rats by comparing them to the controls. 
The use of NA is also advantageous because it does not block the transport of other amino acids 
neurotransmitters, most notably taurine (del Olmo et al., 2004). 
 
Taurine is an abundant non-essential amino acid in the brain formed from cysteine. Traditionally, 
brain taurine is thought to function as an osmoregulator in cells (cell volume regulation), but has 
also been implicated in neuromodulation, possibly functioning as a neurotransmitter. Data exist 
suggesting that taurine functions as an anxiolytic agent (Kong et al., 2006) and interacts with the 
GABAA receptor (Jia et al., 2008). These data make sense given that it has long been recognized 
that taurine and GABA are structurally similar and may share transporters in the brain. 
 
We chose to look at the taurine/GABA relationship in the striatum because it is a known region 
for Mn accumulation (Erikson et al., 2005 and Liu et al., 2000) and because the GABAergic 
medium spiny neurons of the striatum help orchestrate dopaminergic activity in the basal ganglia 
(Ade et al., 2008), where dysfunction is known to contribute to movement abnormalities during 
Mn neurotoxicity (Carlsson and Carlsson, 1990). Microdialysate fractions collected from the 
striatum of rats revealed that taurine release was higher than glutamate and glycine, and that 
overall the striatum is very rich in taurine (Molchanova et al., 2004). To date, however, the effect 
of Mn-exposure on extracellular taurine (TauEC) in the striatum is unknown. Therefore, we 
sought to determine if Mn-exposure effects TauEC concentrations in the striatum possibly as it 
relates to GABA biology. 
 
In addition to GABA and taurine, we felt it was prudent to examine the effect of Mn on another 
amino acid neurotransmitter, glycine. Glycine is an abundant inhibitor neurotransmitter, similar 
to GABA, and it is known that taurine is a glycine receptor agonist (Xu et al., 2006). Although 
previous studies have not shown Mn to have an effect on extracellular glycine (GlyEC) levels in 
the striatum (Takeda et al., 2003), it is possible that glycine levels may be affected due to 
potential alterations in GABA or taurine concentrations driven by NA or Mn-exposure. 
 
Within the brain, astrocytes are the primary cells that maintain the composition of the 
extracellular fluid (Wang and Bordey, 2008). It is logical, therefore, that disturbances in 
GABAEC, GlyEC and TauEC caused by Mn-exposure could be due to astrocyte dysfunction. Thus, 
our final goal of this study was to examine the effect of Mn-exposure on amino acid biology in 
primary astrocyte cultures. 
 
MATERIALS AND METHODS 
Animals 
Male weanling (post-natal day 21) Sprague–Dawley rats (Harlan Sprague–Dawley, Indianapolis, 
IN) (n = 8 for microdialysis study; n = 6 for PCR gene expression and metal analysis studies) 
were randomly divided into two dietary treatment groups used in previous studies (Anderson et 
al., 2007a, Anderson et al., 2007b and Anderson et al., 2008): control (CN; 35 mg Fe/kg, 10 mg 
Mn/kg diet and d.i. water) and Mn-exposed (Mn; control diet and 1 g Mn (as MnCl2)/L d.i. 
water). Diets were obtained from Bio-Serv (Frenchtown, NJ) and certified for metal content. 
Rats had free access to food and water 24 h/day, with the lights off between 1800 and 600 h and 
room temperature maintained at 25 ± 1 °C. The University of North Carolina at Greensboro 
Animal Care and Use Committee approved all of the animal procedures. 
 
Cell cultures 
Rat primary cortical astrocyte cultures were purchased from Invitrogen (Carlsbad, CA) and 
certified for purity with >95% staining positive for the astrocytic marker glial fibrillary acidic 
protein (GFAP). Cells were grown in Dulbecco's Modified Eagle Media (D-MEM) with 15% 
fetal bovine serum (FBS), and maintained in a humidified atmosphere of 95% air/5% CO2 at 
37 °C. Manganese treatments were delivered using 0, 100, or 300 μM Mn in the form of MnCl2. 
These dose concentrations are based on previous studies in non-human primates reporting 
clinical symptoms of Mn neurotoxicity at brain concentrations of 300 μM, while 100 μM 
concentrations appeared to be asymptomatic (Suzuki et al., 1975). For this reason 300 μM was 
use to examine the effect of toxic Mn accumulation on taurine uptake, while 100 and 300 μM 
were used for the mRNA experiments to examine if there is a change in expression of Scl6a6 
from moderate non-symptomatic levels (100 μM) to known toxic accumulation (300 μM). 
 
3H-Taurine 
Uptake of tritiated taurine (3H-Taurine) was measured as described by Erikson and Aschner 
(2002). Astrocytes (cultured for 3–4 weeks, seeded 2 × 105 in 6-well plates, and grown to 
confluence) were incubated overnight at 37 °C with treatment media containing 0 or 300 μM 
MnCl2. The next day, cells were washed 3× with HEPES buffer [122 mM NaCl, 3.3 mM KCl, 
0.4 mM MgSO4, 1.3 mM CaCl2, 1.2 mM KH2PO4, 10 mM glucose, and 25 mM N-2-hydroxy-
ethylpiperanzine N′-2-ethansulfonic acid, pH 7.4] and incubated for 1, 3, or 6 min with HEPES 
buffer containing 0.5 μCi 3H-Taurine (GE Healthcare Life Sciences, Piscataway, NJ). The 
reaction was stopped by aspirating the tritiated HEPES and washing the cells 4× with cold (4 °C) 
290 mM mannitol buffer containing 0.5 mM calcium nitrate to maintain cell adhesion to the 
substrate. Cells were solubilized in 1 mL RIPA lysis buffer (99 mL 1× PBS, 1 mL non-idet 40, 
0.1 g sodium dodecyl sulfate, 0.5 g sodium deoxycholate, pH 7.4) and 750 μL aliquots were used 
for β-counting with a Beckman LS 3801 liquid scintillation analyzer (Beckman Instruments). 
The remaining 250 μL was used for protein determination using the bicinchoninic assay (BCA, 
Pierce Chemicals). 
 
Stereotaxic surgery 
After 5 weeks of dietary treatment and 1 week prior to microdialysis experiments, rats were 
anesthetized with ketamine–HCl (80 mg/kg) and xylazine (12 mg/kg) and maintained on a 
heating pad at 37 °C. The heads of the rats were shaved and wiped with a 5% povidone–iodine 
solution to reduce risk of infection. Sterile instruments and gloves were used throughout the 
surgical procedure. The rats were secured in the stereotaxic frame and an incision was made 
perpendicular to the bregma. A guide cannula (CMA/12, CMA Microdialysis, Acton, MA) was 
implanted into the striatum using the following coordinates: 2.4 mm lateral to the midline, 
7.5 mm anterior to the lambda. The cannula was lowered to a depth of 2.5 mm, positioning it in 
the medial area of the striatum (Paxinos and Watson, 1998). Anchoring screws were utilized to 
maintain the position of the cannula before being cemented into place using dental adhesive. 
Animals were given 0.9% sterile saline (0.5 mL/kg body weight, i.p.) to reduce fluid lost while 
under anesthesia and to aid in recovery time. Animals were also given the xylazine reversal agent 
Antisedan (Atapimazole) (0.1 mg/kg body weight, i.p.) (Allivet, Hialeah, FL) to reduce recovery 
time. Animals were returned to shoebox cages with Tek-Fresh bedding (Harlan, Indianapolis, 
IN) and monitored daily until microdialysis experiments began. 
 
Microdialysis 
During week six of the dietary protocol, a microdialysis probe (CMA/12 Elite, CMA 
Microdialysis, Acton, MA) was inserted into the guide cannula and the rat was perfused with 
artificial cerebral spinal fluid (aCSF) (155 mM Na+, 0.83 mM Mg2+, 2.9 mM K+, 132.76 mM 
Cl−, 1.1 mM Ca+, pH 7.4) for 1 h at a flow rate of 1 μL/min. After perfusion, the flow rate was 
adjusted to 0.5 μL/min and 30 min fractions were collected in microtubes for a total of four and a 
half hours (9 samples per rat) in a refrigerated fraction collector (CMA Microdialysis, Acton, 
MA). This protocol has been used successfully in previous studies with stable neurotransmitter 
recovery in the dialysate (Anderson et al., 2008 and Anderson et al., 2009). Probe recoveries 
measured using in vitro standards for GABA, taurine, and glycine were averaged for each amino 
acid over all probes; however, because tissue diffusion may affect in vivo probe recovery no 
correction was made for total recovery as in previous studies (Anderson et al., 2008, Anderson et 
al., 2009, Beard et al., 1994, Chen et al., 1995 and Nelson et al., 1997). The microdialysate 
samples analyzed were collected at 0, 60, 120, 180, and 240-min time-points with NA 
administration (100 μM in aCSF) just prior to the 60-min collection. This time course identifies 
baseline values (0 min), the response of extracellular amino acid concentrations to decreased 
GAT function (60 min), their recovery after removal of NA and re-perfusion with aCSF 
(120 min), and renormalization (180 and 240 min). Samples were stored at −80 °C until analysis 
of the dialysate fraction. Rats were then returned to their home cage, and, the following day, 
were euthanized, brains removed, and probe placement verified post-mortem. 
 
CE-LIF analysis 
A protocol by Chen et al. (2001) allowing for detection of amino acids and biogenic amines at 
nanomolar concentrations, modified to accommodate the needs of our previous studies 
(Anderson et al., 2008 and Anderson et al., 2009), was utilized in the current study as well. The 
advantages of applying CE analysis to neuroactive compounds include minimal required sample 
volumes, speed of analysis, and high separation efficiency (Powell and Ewing, 2005). Briefly, on 
the day of sample analysis, 5 μL of microdialysate sample was derivatized at 40 °C by the 
addition to 100 nmol ATTO-TAG™ FQ fluorogenic reagent (Molecular Probes, Eugene, OR) 
and 10 μL of a 10 mM borate (Fisher, Fair Lawn, NJ)/25 mM KCN (Fluka) solution (pH 9.18). 
The total sample volume was adjusted to 20 μL using HPLC grade methanol (G.J. Chemical 
Company, Newark, NJ). After a minimum reaction time of 90 min, 1 μL of an FQ derivatized 
homoserine (Sigma, St. Louis, MO) internal standard solution was added to the derivatized 
microdialysate sample and analyzed. CE-LIF conditions leading to high efficiency peaks for 
microdialysate samples were 10 kV for 10 min with sample injections at 10 psi/s. Uncoated silica 
capillary (Polymicro, Arizona) with an i.d. of 25 μm, o.d. of 361 μm, and effective/total lengths 
of 25.4/30.0 cm was used. The run buffer was 15 mM sodium borate (Fisher), pH 9.0, with 
45 mM sodium dodecyl sulfate (Pierce, Rockford, IL), 5 mM sodium cholate (Anatrace, 
Maumee, OH), and 4% (v/v) 2-propanol (Fisher). Three replicates were analyzed for each 
sample, with calibration curves for neurotransmitters of interest constructed each day of sample 
analysis using three points with a concentration range of 0.1–5 μM. GABA (Sigma), glycine 
(Sigma), taurine (Sigma), and homoserine standard solutions used for construction of calibration 
curves were prepared in ACSF with the same composition as that used in the microdialysis 
studies. The ratio of neurotransmitter peak height to internal standard (homoserine) peak height 
for each sample was used to determine the concentration of the neurotransmitter based on the 
calibration curve response. 
 
RNA isolation and cDNA synthesis 
Total RNA was isolated from astrocyte monolayers and the striatum of control and Mn-exposed 
rats for quantitative PCR analysis. Tissue samples were stored in 1 mL of RNAlater® solution 
(Ambion Inc., Austin, TX) and kept at −80 °C until analysis. Astrocytes were cultured in 6-well 
plates, then treated for 24 h with media containing 0, 100, or 300 μM Mn. Astrocytes were 
harvested in 500 μL denaturation solution (Ambion Inc., Austin, TX). Tissue and cell culture 
RNA isolation were performed using the ToTALLY RNA™ system (Ambion Inc., Austin, TX), 
following manufacturer's instructions. RNA concentration and purity were determined by 
spectrophotometric analysis before carrying out cDNA synthesis. Synthesis of cDNA was 
performed using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, 
Foster City, CA), following manufacturer's instructions. 
 
Quantitative PCR 
Quantitative real-time PCR analysis was utilized to determine differential mRNA expression 
between control and Mn-treated tissue or cell samples of the solute carrier family taurine 
transporter Slc6a6 (Applied Biosystems, Foster City, CA; Rn00567962_m1, Chr. 4 – 
125875817–125945795). Triplicate aliquots of cDNA were analyzed on 96-well plates using 
TaqMan® Gene Expression assays (Applied Biosystems, Foster City, CA). Values of cDNA 
expression were normalized relative to the expression of β-actin (Rn00667869_m1, Chr. 12 – 
12047070–12050040) analyzed from the same sample on the same plate and reported as percent 
of control. 
 
 
 
Metal analyses 
Mn, Fe, and copper (Cu) concentrations were measured with graphite furnace atomic absorption 
spectrometry (Varian AA240, Varian, Inc., USA). Brain tissue from the striatum was digested in 
ultra-pure nitric acid (1:10, w/v dilution) for 48–72 h in a sand bath (60 °C). A 50 μL aliquot of 
digested tissue was brought to 1 mL total volume with 2% nitric acid for analysis. The 
extracellular striatal samples obtained via microdialysis were not diluted due to the small volume 
(20 μL) and the likelihood that this biological compartment has a low concentration of metals. 
Bovine liver (NBS Standard Reference Material, USDC, Washington, DC) (10 μg Mn/g; 184 μg 
Fe/g; 80 μg Cu/g) was digested in ultra-pure nitric acid and used as an internal standard for 
analysis (final concentration 5 μg Mn/L; 92 μg Fe/L; 10 μg Cu/L). 
 
Statistical analysis 
Data were analyzed using SPSS v14 for Windows (Microsoft, Redmond, WA). Metal, baseline 
microdialysis, and 3H-Taurine uptake data were analyzed using paired-samples t-tests to examine 
the difference between Mn-treated samples and controls. Independent sample t-tests were used to 
examine time-point percent change differences in the microdialysis data, time-point 3H-Taurine 
uptake changes, and significance between Mn-exposed versus control mRNA expression of 
Scl6a6. A p-value of <0.05 was considered significant. 
 
RESULTS 
Manganese and iron concentrations 
Mn-exposure resulted in significant alterations in compartmental metal concentrations. As 
expected, tissue Mn levels were significantly higher in Mn-exposed rats versus control 
(p = 0.001) (Table 1). Cu levels were slightly increased with Mn-exposure, and no appreciable 
difference was observed in Fe levels between the two groups; however, there was a significant 
reduction (p = 0.002) in the Fe:Mn ratio in the Mn-exposed group (Table 1). Examining Fe and 
Mn as a ratio may portray metal toxicities more accurately. The use of an Fe:Mn ratio has 
recently emerged as a reliable diagnostic criteria for metal neurotoxicities, as levels of one 
divalent cation may alter the availability or functionality of the other (Chua and Morgan, 1996, 
Cowan et al., 2009 and Fitsanakis et al., 2008). 
 
Table 1: Brain tissue and extracellular metal concentrations. 
 Extracellular (μM)  Ratio 
 Mn Fe Cu  Fe:Mn 
Control 0.023 ± 0.006 4.071 ± 0.510 –  5044:1 
Manganese 0.104 ± 0.030* 1.526 ± 0.304** –  137:1* 
 Striatum (nmol/mg protein)  Ratio 
 Mn Fe Cu  Fe:Mn 
Control 0.185 ± 0.029 3.896 ± 0.106 0.793 ± 0.085  25:1 
Manganese 0.477 ± 0.059** 3.329 ± 0.407 0.975 ± 0.089  9:1* 
Compartmental metal concentrations represented in the striatum of Mn-exposed rats. Extracellular metal concentrations represent Mn and Fe 
levels measured in microdialysate fractions of extracellular fluid collected from the rat striatum (n = 4). Striatal Mn, Fe, and Cu levels represent 
metal concentrations of brain tissue (n = 6). The Fe:Mn ratio depicts metal homeostasis changes due to Mn accumulation. A significant increase 
in extracellular Mn accompanied by significant decreases in both Fe levels and the Fe:Mn ratio were observed in rats exposed to Mn treatment. 
No significant changes in tissue Fe levels were observed; however, a significant reduction in the Fe:Mn ratio indicates altered metal homeostasis. 
*p < 0.05 versus control according to paired-sample t-test analysis. 
**p ≤ 0.001 versus control according to paired-sample t-test analysis. 
 
Collected fractions of microdialysate were analyzed for Fe and Mn to assess changes in 
extracellular metal levels as a consequence of oral Mn-exposure. Extracellular Mn within the 
striatum was significantly increased in the Mn-exposed rats, while Fe levels significantly 
decreased, compared to controls (p = 0.021 and 0.001, respectively) (Table 1). Differences in 
extracellular metal concentrations between Mn-exposed and control groups revealed a significant 
(p = 0.020), 36-fold, decrease in the extracellular Fe:Mn ratio due to increased Mn (Table 1). 
 
Extracellular concentrations of taurine, GABA, and glycine 
Extracellular amino acid concentrations are differentially altered by Mn-exposure. Baseline 
levels of taurine and glycine were more abundant than GABA in the extracellular space, though 
Mn does not have a statistically significant effect on their levels compared to control (Fig. 1). 
Mn-exposure, however, did significantly increase (p = 0.017) baseline GABA concentrations 
over control (Fig. 1A), corroborating our previous findings (Anderson et al., 2007a, Anderson et 
al., 2007b and Anderson et al., 2008). While GABAEC was more concentrated in the striatum of 
Mn-exposed rats, the rise in NA-induced GABA levels was not as profound in Mn-exposed 
versus control rats (Fig. 1C). Administration of NA caused a significant 228% increase in the 
GABAEC levels of the control (p = 0.015) but not in the Mn-exposed group (p = 0.233) (Fig. 
1C). After the removal of NA and a 60-min perfusion with aCSF, GABA levels returned to 
baseline and remained unchanged at the 180- and 240-min time-points (data not shown). 
 
 
 
Fig. 1: Extracellular amino acids concentrations. Microdialysate fractions from the striatum of control (n = 4) and 
Mn-exposed (n = 4) rats were analyzed for taurine, GABA, and glycine concentrations at baseline, 60 min, and 
120 min. Nipecotic acid (NA) was administered prior to the 60-min time-point. Graph values are expressed as 
percent change ± SEM; inset data are μM concentrations ± SEM. (A) Baseline concentrations of each amino acid at 
onset of sample collection (0 min) in both control and Mn-exposed rats. Percent change in amino acid concentration 
was calculated from baseline (100%) to post-NA administration, then post-NA to 120-min recovery period for (B) 
taurine, (C) GABA, and (D) glycine to observe the effect of Mn on extracellular amino acid levels. Superscript 
letters denote significant within-group differences (bars with different letters are significantly different from one 
another, bars that share a letter are not significant from one another), while * denote significance between groups. a, 
b, c, and *p < 0.05 via independent samples t-test within or between groups. 
No significant difference in baseline taurine levels was found between control and Mn-exposed 
animals (Fig. 1A). In control animals administration of NA caused a modest 75% decline in 
TauEC from baseline, followed by a significant (p = 0.010) 1000% increase after removal of NA 
at the 120 min time-point (Fig. 1B). The decrease in TauEC was similar in the Mn-exposed group 
due to NA administration; however, no rise in TauEC was observed after removal of NA, as 
observed in the control rats (Fig. 1B). In control and Mn-exposed animals, taurine levels returned 
to and maintained levels similar to baseline at the 180- and 240-min time-points (data not 
shown). 
 
GlyEC levels were similar in control and Mn-exposed groups, and no significant percent changes 
were observed between time-points within either control or Mn groups (Fig. 1D). 
 
Limits of detection of the CE-LIF method employed for each neurotransmitter were found by 
serial dilution of derivatized standards until no discernable analyte peak could be obtained. 
Accordingly, limits of detection for GABA, glycine, and taurine were 6.9 ± 1.7 nM, 24 ± 5 nM, 
and 42 ± 21 nM, respectively, with linear dynamic ranges of 3.6 decades, 3.1 decades, and 3.3 
decades, respectively. 
 
3H-Taurine uptake 
Mn-exposure results in increased 3H-Taurine uptake in astrocytes. After observing the unique 
effects of Mn-exposure on TauEC in the striatum of rats in vivo, we decided to examine the effect 
of Mn-exposure on 3H-Taurine uptake in primary rat astrocytes in vitro. Primary astrocytes 
exposed to Mn revealed a slight (30%) decrease in taurine uptake after 1 min, followed by a 
significant (219%) increase after 3 min (p = 0.034) (Fig. 2). Six minute 3H-Taurine retention in 
Mn-exposed cells was similar to that of controls. Uptake of 3H-Taurine in control cells remained 
consistent around 0.4 pmol/mg protein at each time-point (Fig. 2, inset). To examine whether or 
not 24 h Mn-exposure had an effect on taurine transporter expression in astrocytes, we next 
evaluated Mn-induced alterations in the taurine transporter, Slc6a6. 
 
 
Fig. 2: 3H-Taurine uptake in primary astrocytes. Primary astrocytes, seeded 2 × 10−5 in 6-well plates (n = 6) then 
grown to confluence, were cultured with either Mn-treated (300 μM MnCl2) or control media. After 24 h cultures 
were exposed to 3H-Taurine for 1, 3, or 6 min and analyzed for 3H-Taurine retention. The inset represents percent 
change in uptake due to Mn-exposure expressed as percent control ± SEM. A significant (p = 0.034) increase in 3H-
Taurine uptake was observed after 3 min of exposure in the Mn-treated astrocytes versus control. *p < 0.05 via 
independent samples t-test between Mn and control treatment groups at each time-point. 
Gene expression of taurine transporter 
Mn-exposure increased taurine transporter gene expression in the rat brain, but not cultured 
astrocytes. Quantitative RT-PCR analysis was conducted on primary astrocytes and striatal brain 
tissue to determine whether or not taurine transporter (Slc6a6) gene expression reflected the 
observed Mn-induced alterations in TauEC and 3H-uptake. Chronic Mn-exposure caused a 
significant (p = 0.045) increase in striatal Slc6a6 mRNA levels compared to control (Fig. 3). 
Alternatively, acute Mn-exposure (100 and 300 μM Mn) had relatively little effect on astrocyte 
Slc6a6 mRNA levels (Fig. 3). 
 
 
Fig. 3: Taurine transporter, Slc6a6, mRNA levels. Quantitative RT-PCR results for taurine transporter, Slc6a6, in 
Mn-exposed astrocytes (n = 6) and the striatum of Mn-exposed rats (n = 6). Values are expressed as percent 
control ± SEM, with control values representing no Mn-exposure. Minimal alterations in Slc6a6 levels were 
observed in astrocytes treated with either 100 or 300 μM MnCl2. Mn-exposure did, however, significantly increase 
Slc6a6 mRNA levels within the caudate putamen, versus matched control animals. *p < 0.05 via independent 
samples t-test between Mn and control treatment groups. 
 
DISCUSSION 
The purpose of this study was to examine the effect of Mn on GAT-mediated GABA uptake. 
Knowing that glycine and taurine are important amino acid neurotransmitters that are known to 
modulate GABA neurochemistry (Namima et al., 1982 and Hernandes and Troncone, 2009), it 
was logical that we measure them in the dialysate too. We found that GAT function is attenuated 
by Mn-exposure, and that the resulting increase in GABAEC alters taurine but not glycine 
homeostasis. Specifically, we observed a 10-fold increase in TauEC upon removal of NA in the 
control animals but not in the Mn-exposed, implicating a critical neurotransmitter function of 
TauEC that Mn alters (discussed in more detail below and in Fig. 4). 
 
 
Fig. 4: Working model for Mn-induced GABA and taurine alterations. The dynamic shifts in neurotransmitter 
concentrations observed in response to nipecotic acid (NA) (panels A, B, and C) are mitigated by Mn (panels D, E, 
and F). We hypothesize this lack of response in Mn-exposed rats is driven by decreased GABA transporter (GAT-1) 
function. (A) The control panel displays GABAEC and TauEC under normal conditions, representing baseline 
microdialysis measurements. All percent change (% change) comparisons in subsequent panels are based on the % 
change from baseline levels, represented in the control panel. Under normal conditions GABAEC binds to GABAA 
receptors (GABAA-R) allowing chloride ion (Cl2−) movement for inhibitory hyperpolarization of post-synaptic 
neurons, while pre-synaptic binding to GABAB receptors (GABAB-R) regulates GABA release (Kamisaki et al., 
1993) through slow G-protein-linked inhibitory tone via GABAB activation (Chen and van den Pol, 1998). GAT-1 
functions normally to clear excess GABA from the synapse as TauEC modulates pre- and post-synaptic transmission 
( [Namima et al., 1982] and [Namima et al., 1983]). (B) Administration of NA, a GAT specific inhibitor, blocks 
GABA reuptake substantially increasing GABAEC while decreasing TauEC. Additionally, NA activates GABAA-like 
Cl2− channels (Barrett-Jolley, 2001) in addition to GAT binding, increasing the pre- and post-synaptic inhibitory 
tone. (C) Upon removal of the NA, GABAEC returns to normal; however, a 10-fold increase in TauEC ensues. We 
speculate that the taurine efflux is a compensatory response to regulate GABA release through GABAB activation 
(Chen and van den Pol, 1998). Elevated TauEC may also function to stabilize the inhibitory tone achieved in the 
striatum due to increased GABAA activation ( [del Olmo et al., 2000] and [Jia et al., 2008]). TauEC slowly returns to 
control levels over the next two hours (data not shown), indicating the acute nature of this response. (D) During Mn-
exposure, GABAB expression is decreased (Anderson et al., 2008) and GABA reuptake via GAT-1 is attenuated, 
resulting in higher GABAEC and lower TauEC (Fig. 1B and C) compared to control. We hypothesize that this 
alteration in GAT-1 function is regulated by Mn activation of protein kinase C (PKC) (Latchoumycandane et al., 
2005) causing phosphorylation of GAT-1 and subsequent internalization (Gadea and López-Colomé, 2001). This 
internalization decreases synaptic density of GAT-1 and attenuates GABA reuptake. Additionally, decreased 
GABAB expression alters auto-receptor feedback resulting in significantly higher GABAEC compared to normal 
conditions. (E) Mn-exposure significantly attenuates the effects of NA, potentially via decreased synaptic 
availability of GAT-1. The attenuated rise in GABAEC coupled with decreased auto-receptor expression results in 
less GABAA and GABAB activation leading to reduced inhibitory tone compared to control. (F) Removal of NA in 
Mn-exposed rats led to GABAEC returning to pre-NA levels (panel D); however, the taurine efflux was absent 
compared to control (refer to Fig. 1B). We interpret the dramatically decreased taurine efflux observed with Mn-
exposure as a function of altered auto-receptor biology (Anderson et al., 2008). Altered feedback regulation in 
conjunction with a modest rise (40%) in GABAEC, compared to the normal feedback regulation and significant rise 
(228%) in GABAEC observed in control rats, leads to an uncoupling of the taurine efflux response due to Mn-
exposure. Our studies suggest that Mn-exposure disrupts extracellular conditions within the striatum, altering 
neurochemical coordination with other brain regions. Elucidating the mechanism involved in this response will 
further the development of pharmacological therapies aimed at susceptible populations. 
 
Mn, Fe, and Cu levels were analyzed in the striatum of Mn-exposed rats and non-exposed 
controls to ascertain homeostatic changes due to Mn accumulation. As expected, Mn-exposure 
led to significant Mn accumulation in the striatum (Table 1). Striatal Cu levels were slightly 
higher with Mn-exposure, but tissue Fe levels were unaffected. These data are consistent with 
striatal Fe levels reported in previous studies with Mn-exposure (Anderson et al., 2009, Erikson 
et al., 2004 and Fitsanakis et al., 2008). However, there was a near 3-fold decrease in the Fe:Mn 
ratio with Mn-exposure, suggesting altered metal homeostasis. While tissue levels of Fe 
remained relatively unchanged, extracellular Fe was significantly decreased by Mn 
accumulation, with a 36-fold drop in the Fe:Mn ratio. Previously, Mn-driven decreases in 
extracellular Fe have been positively correlated with extracellular norepinephrine levels and 
inversely associated with GABAEC (Anderson et al., 2008 and Anderson et al., 2009), but no 
significant changes in tissue Fe levels were observed. The disparity between tissue and 
extracellular Fe:Mn ratios suggest the synaptic environment may be subject to drastic changes in 
metal homeostasis. Moreover, these changes may leave the extracellular compartment vulnerable 
compared to striatal tissue, in which Fe and Mn levels appear to be more tightly regulated. 
 
We specifically selected the striatum to examine the effect of Mn on GABAEC and GAT function 
because it is a known region for Mn accumulation (Erikson et al., 2005 and Liu et al., 2000), and 
due to its high density of GABAergic cell bodies (Oertel and Mungnaini, 1984). Mn-exposure 
has been associated with increased GABAEC concentrations in the striatum, and decreased 3H-
GABA uptake has been reported in striatal synaptosomes (Anderson et al., 2007a, Anderson et 
al., 2007b and Anderson et al., 2008). While these studies reported little effect on GAT protein 
and mRNA levels with Mn-exposure, the implications of these data on GAT functionality 
prompted us to pharmacologically probe GAT function with NA. We hypothesized that Mn-
exposure alters GAT function as indicated by the attenuation of increased GABAEC 
concentrations in the presence of NA. Results from the microdialysis experiment indicate that 
this is indeed the case. NA in the striatum of control rats caused a 228% increase in GABAEC; 
however, in Mn-exposed rats NA only increased GABAEC by 43%. The use of NA in the current 
study identifies GAT as a target for Mn toxicity, and provides an explanation for the observed 
increase in GABAEC with Mn accumulation. Exactly how Mn regulates GAT function warrants 
further investigation; however, decreased GAT function may be regulated through protein kinase 
C (PKC) activation. Mn-exposure has been shown to activate PKC in N27 mesenchephalic cells 
(Latchoumycandane et al., 2005), and PKC activation has been demonstrated to decrease 3H-
GABA transport by GAT (Sato et al., 1995). Moreover, phosphorylation of GAT-1 via PKC 
(Mandela and Ordway, 2006) may lead to internalization of GABA transporters (Gadea and 
López-Colomé, 2001). This could explain why Anderson et al. (2008) found increased GABAEC 
despite no decrease in GAT-1 protein levels (as detected by western blot analysis which would 
measure both plasma membrane and internalized GAT-1 levels). It is also possible that Mn may 
alter some sort of feedback mechanism such as an auto-receptor (e.g., GABAB or GABAA). 
Being that taurine is a known modulator of GABA receptors (del Olmo et al., 2000, Kamisaki et 
al., 1993, Jia et al., 2008, Namima et al., 1982 and Namima et al., 1983), perturbations in taurine 
biology may play a role in GABA homeostasis. 
 
A novel finding from our study was that control rats responded to cessation of NA with a 10-fold 
increase of TauEC in the striatum, an effect that was absent in the Mn-exposed rats. Changes in 
TauEC coincided inversely with alterations in GABA (Fig. 1A and B), presumably due to its role 
in osmoregulation. These results suggest that alterations in GABA uptake may dictate taurine 
release due to a hyperosmotic environment. Alternatively, the 10-fold increase in taurine after 
removal of NA may be a compensatory response to help decrease GABAEC concentrations. 
Taurine binding to GABAA receptors (del Olmo et al., 2000 and Jia et al., 2008) and GABAB 
auto-receptors (Kamisaki et al., 1993, Namima et al., 1982 and Namima et al., 1983), may help 
to regulate GABA release. Enhanced taurine efflux observed in control animals after NA 
administration could functionally decrease GABA release by activating GABAA and GABAB 
receptors thereby normalizing GABAEC. Additionally, there is evidence that NA activates 
GABAA-like ion channels (Barrett-Jolley, 2001). Taurine efflux may be an adaptive response to 
facilitate GABAA activation compensating for the loss of inhibitory tone due to NA cessation. 
Whether the taurine response observed in the control rats is due to its role in regulating striatal 
neurochemistry or through a secondary osmoregulatory effect, the lack of this response in the 
Mn-exposed rats may have profound consequences (see Fig. 4). 
 
Because Mn alters GAT function and GAT transport proteins are in the solute carrier protein 
family Slc6 (shared by the taurine transporter, Slc6a6), it is reasonable to assume that Mn may 
influence taurine movement by altering the function of the taurine transporter. In cultured 
astrocytes we measured 3H-Taurine uptake and found that while Mn initially decreased taurine 
uptake by 30%, it was followed by a significant 219% increase in uptake before normalizing to 
control levels (Fig. 2). Uptake of 3H-Taurine in control cells remained consistent around 
0.4 pmol/mg protein at each time-point, suggesting that fluctuations in taurine uptake in vitro is 
probably due to osmoregulation or altered transporter kinetics. Taurine transporter Slc6a6 
mRNA levels were not altered in cultured astrocytes exposed to 100 or 300 μM Mn. Similar 
results were found by Erikson and Aschner (2002), with Slc6a6 expression significantly 
increasing in astrocytes only when exposed to 500 μM Mn. It is important, however, to 
remember that taurine transport may also occur via volume-sensitive organic osmolyte anion 
channels (VSOACs) (Mongin et al., 1999). VSOACs allow the transport of Na+, K+, Cl−, and 
organic osmolytes (e.g., taurine) under conditions of cell shrinkage or swelling (Lang, 2007). 
Without directly inhibiting Slc6a6, controlling osmolarity, and taking into account Cl− influx due 
to GABAA activation we cannot confirm the functionality of Slc6a6 in the presence of Mn. 
Interestingly, Slc6a6 mRNA levels are increased in the striatum of Mn-exposed rats, compared 
to control (Fig. 3). The contradiction of in vivo and in vitro Slc6a6 expression may be a product 
of chronic (6 week) exposure to Mn in vivo versus acute (24 h) exposure in vitro. Additionally, 
Slc6a6 gene expression is increased in the absence of sufficient taurine, and decreased when 
taurine is in excess (Bitoun and Tappaz, 2000 and Lambert, 2004). Therefore, it is likely that 
altered taurine homeostasis in the striatum due to Mn-exposure influences striatal Slc6a6 
expression similarly. 
 
Collectively, our data show that the GABAEC and TauEC are indeed influenced by Mn 
accumulation and altered GAT function. Moreover, Mn virtually abolished TauEC and 
dramatically blunted the taurine rebound observed during the post-NA recovery period (Fig. 
2 and Fig. 4), indicating a serious disconnect in taurine homeostasis in the Mn-exposed rat 
striatum. Moving forward, it is essential to understand the effect of Mn toxicity on taurine 
movement in the brain. Characterizing the role of Mn on GABA and taurine may help depict the 
multifaceted etiology of Mn neurotoxicity, and provide insight into some of the behavioral 
changes observed with Mn accumulation. 
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